Docket:
A-318-13
Citation: 2014 FCA 17
CORAM:
SHARLOW J.A.
WEBB J.A.
NEAR J.A.
BETWEEN:
|
NOVARTIS PHARMACEUTICALS CANADA INC.
|
Appellant
|
and
|
COBALT PHARMACEUTICALS COMPANY and THE MINISTER OF HEALTH
|
Respondents
|
and
|
NOVARTIS AG and ROCHE DIAGNOSTICS GmbH
|
Respondents/Patentees
|
Heard
at Toronto, Ontario, on January
23, 2014.
Judgment delivered at
Ottawa, Ontario, on January 27, 2014.
REASONS FOR JUDGMENT BY: SHARLOW J.A.
CONCURRED IN BY: WEBB
J.A.
NEAR J.A.
Docket:
A-318-13
Citation: 2014 FCA 17
CORAM:
SHARLOW J.A.
WEBB J.A.
NEAR J.A.
BETWEEN:
|
NOVARTIS PHARMACEUTICALS CANADA INC.
|
Appellant
|
and
|
COBALT PHARMACEUTICALS COMPANY AND THE MINISTER OF HEALTH
|
Respondents
|
and
|
NOVARTIS AG AND ROCHE DIAGNOSTICS GMBH
|
Respondents/Patentees
|
REASONS
FOR JUDGMENT
SHARLOW J.A.
[1]
This is an appeal of the decision of Justice Hughes (2013 FC 985)
dismissing the application of Novartis Pharmaceuticals Canada Inc. under the Patented
Medicines (Notice of Compliance) Regulations (SOR/93-133) for an order
prohibiting the Minister of Health from issuing a notice of compliance to
Cobalt Pharmaceuticals Company for a generic version of
a drug containing zoledronic acid to be administered in once-yearly doses for
the treatment of osteoporosis, until after the expiry of Canadian Patent No. 2,410,201.
[2]
Cobalt alleged that the 201 patent is invalid for want of patentable
subject matter. Justice Hughes found that allegation to be justified because
the claims essentially are for a method of medical treatment as explained in Tennessee
Eastman Co. v. Commissioner of Patents, [1974] S.C.R. 111. Novartis argues
that this conclusion is wrong in law. I do not agree.
[3]
To accept the argument of Novartis it would be necessary to conclude in
the face of Tennessee Eastman that a method of medical treatment is
patentable subject matter, or to conclude that Justice Hughes misconstrued the
patent. Having carefully considered the argument of Novartis and the
authorities to which the Court was referred, I am unable to reach either
conclusion.
[4]
For that reason, I would dismiss the appeal with costs.
“K. Sharlow”
“I agree
Wyman W. Webb J.A.”
“I agree
D. G. Near J.A.”
FEDERAL COURT OF APPEAL
NAMES OF COUNSEL AND SOLICITORS OF RECORD
Docket:
A-318-13
(APPEAL FROM A JUDGMENT OR ORDER OF THE HONOURABLE
MR. JUSTICE HUGHES, DATED SEPTEMBER 25, 2013, DOCKET NO. T-724-12)
STYLE OF CAUSE:
|
NOVARTIS PHARMACEUTICALS CANADA INC. v.
COBALT PHARMACEUTICALS COMPANY and THE MINISTER OF HEALTH
and NOVARTIS AG and ROCHE DIAGNOSTICS GmbH
|
PLACE OF HEARING:
Toronto, Ontario
DATE OF HEARING:
January
23, 2014
REASONS FOR
JUDGMENT BY:
SHARLOW
J.A.
CONCURRED IN BY: WEBB,
NEAR JJ.A.
DATED:
January 27, 2014
APPEARANCES:
Anthony G. Creber
Livia Aumand
|
For The Appellant
|
Douglas N. Deeth
Kavita Ramamoorthy
|
For The Respondents
|
SOLICITORS OF RECORD:
Gowling Lafleur Henderson LLP
Ottawa, Ontario
|
For The Appellant
|
Deeth Williams Wall LLP
Toronto, Ontario
|
For The Respondents
|